Go to the page content
Diabetes

A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes

Locations

Not recruiting

Start date

01/12/2025

Identifiers

Trial ID NN9924-8485,
NCT number NCT07271251,
Eudract number Not Available

Summary

The purpose of the study is to find out if the new tablet formulation oral semaglutide D is equally safe and effective as the approved oral semaglutide for treating Japanese people with type 2 diabetes. Participants will receive either oral semaglutide D (the treatment being tested) or oral semaglutide (the comparator); which treatment a participant gets is decided by chance. Oral semaglutide is an approved tablet (a treatment used as a comparator), while oral semaglutide D is described as the new tablet formulation being tested in this study. The study will last approximately 27 weeks.

Trial Overview:

Condition

Type 2 Diabetes

Treatment

DRUG: Oral semaglutide

Study type

INTERVENTIONAL

Trial duration

Dec 01 2025 - Aug 21 2026

Participants

264

Phase

III

Are you eligible?

Gender

Male and female

Age

18 years and older

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.